<DOC>
	<DOCNO>NCT02583568</DOCNO>
	<brief_summary>A need investigation fluorescence image-guided surgery breast conserving surgery ( BCS ) arise follow result obtain phase I feasibility breast cancer trial ( BIRDYE study : ABR NL 37479.042011 ) . The aim study define optimal dose fluorescent tracer Bevacizumab-IRDye800CW intraoperative delineation breast cancer tissue use improve optimized fluorescent tracer camera system .</brief_summary>
	<brief_title>Fluorescence Guided Surgery Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Main 1 . Females age ≥ 18 year . 2 . Confirmed diagnosis breast cancer mean histology cytology eligible breast cancer surgery . 3 . Tumor size ≥ 5 mm ( 0 , 5 cm ) diameter accord anatomical imaging data . 4. WHO performance score 02 . 5 . Life expectancy great 12 week 6 . Written inform consent obtain 7 . In Investigator 's opinion , patient able willing comply trial requirement . For female subject childbearing potential , premenopausal intact reproductive organ le 2 year postmenopausal : 8 . A negative serum pregnancy test prior receive second generation tracer 9 . Willing ensure partner us effective contraception trial 3 month thereafter . Main 1 . Medical psychiatric condition compromise patient 's ability give inform consent 2 . Breast prosthesis target breast 3 . History infusion reaction Bevacizumab monoclonal antibody therapies 4 . Concurrent anticancer therapy ( chemotherapy , radiotherapy , vaccine , immunotherapy ) deliver within last 6 week prior start treatment 5 . Significant renal hepatic impairment . 6 . Inadequately controlled hypertension without current antihypertensive medication . 7 . History myocardial infarction , transient ischemic attack , cerebro vascular accident , pulmonary embolism , uncontrolled congestive heart failure ( CHF ) , significant liver disease , unstable angina within 6 month prior enrollment . 8 . Patients receive anticoagulant therapy vitamin K antagonists . 9 . Patients receive Class IA ( e.g . Quinidine ) Class III ( e.g . Dofetilide , Amiodarone , Sotalol ) antiarrhythmic agent . 10 . Evidence QT prolongation pretreatment ECG ( Males &gt; 440 m , Females &gt; 450 m ) . 11 . Magnesium , potassium calcium level low normal limit regard clinically relevant regard study participation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>image-guided surgery</keyword>
</DOC>